25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ERNA (Eterna Therapeutics Inc) Stock Analysis
Buy, Hold or Sell?

Let's analyze Eterna Therapeutics Inc together

I guess you are interested in Eterna Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Eterna Therapeutics Inc’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Eterna Therapeutics Inc’s Price Targets

I'm going to help you getting a better view of Eterna Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Eterna Therapeutics Inc

I send you an email if I find something interesting about Eterna Therapeutics Inc.

1. Quick Overview

1.1. Quick analysis of Eterna Therapeutics Inc (30 sec.)










1.2. What can you expect buying and holding a share of Eterna Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
34.3%

What is your share worth?

Current worth
$0.03
Expected worth in 1 year
$0.02
How sure are you?
37.1%

+ What do you gain per year?

Total Gains per Share
$-0.01
Return On Investment
-5.2%

For what price can you sell your share?

Current Price per Share
$0.19
Expected price per share
$0 - $0.25
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Eterna Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)
$0.19
Intrinsic Value Per Share
$-4.81 - $0.26
Total Value Per Share
$-4.78 - $0.30

2.2. Growth of Eterna Therapeutics Inc (5 min.)




Is Eterna Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$1.7m$4.2m-$18.1m-130.6%

How much money is Eterna Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$11.1m-$5.4m-$5.7m-51.4%
Net Profit Margin-151,817.3%-11,789.2%--

How much money comes from the company's main activities?

2.3. Financial Health of Eterna Therapeutics Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Eterna Therapeutics Inc?

Welcome investor! Eterna Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Eterna Therapeutics Inc.

First you should know what it really means to hold a share of Eterna Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Eterna Therapeutics Inc is $0.1891. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Eterna Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Eterna Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.03. Based on the TTM, the Book Value Change Per Share is $0.00 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.05 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Eterna Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.11-58.3%-0.21-112.7%-0.10-52.6%-0.21-111.2%-0.12-65.6%
Usd Book Value Change Per Share0.90476.7%0.00-1.3%-0.05-25.0%0.00-2.4%0.00-1.6%
Usd Dividend Per Share0.000.1%0.000.0%0.000.1%0.000.1%0.000.0%
Usd Total Gains Per Share0.90476.8%0.00-1.3%-0.05-24.9%0.00-2.3%0.00-1.6%
Usd Price Per Share0.29-1.39-2.41-3.21-3.68-
Price to Earnings Ratio-0.66--2.55--6.32--7.08--112.39-
Price-to-Total Gains Ratio0.32--10.53--129.29-804.80-624.54-
Price to Book Ratio8.91--10.07-32.17-22.64-36.60-
Price-to-Total Gains Ratio0.32--10.53--129.29-804.80-624.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.1891
Number of shares5288
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (5288 shares)-13.06-22.98
Gains per Year (5288 shares)-52.23-91.90
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
12-54-622-94-102
23-108-1144-188-194
35-162-1666-282-286
46-215-2188-376-378
58-269-27011-470-470
610-323-32213-564-562
711-377-37415-658-654
813-431-42617-752-746
915-485-47819-846-838
1016-538-53021-940-930

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.034.00.02.9%3.056.00.05.1%
Book Value Change Per Share1.03.00.025.0%3.07.02.025.0%5.013.02.025.0%11.022.02.031.4%21.036.02.035.6%
Dividend per Share2.00.02.050.0%9.00.03.075.0%12.00.08.060.0%12.00.023.034.3%12.00.047.020.3%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%7.013.00.035.0%13.022.00.037.1%23.036.00.039.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Eterna Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.901-0.003+100%-0.047+105%-0.004+100%-0.003+100%
Book Value Per Share--0.033-0.266+918%0.082-60%0.057-43%0.073-55%
Current Ratio--0.8010.611+31%0.985-19%2.201-64%1.857-57%
Debt To Asset Ratio--0.6772.453-72%0.829-18%1.079-37%0.903-25%
Debt To Equity Ratio--2.0980.524+300%11.716-82%4.014-48%3.369-38%
Dividend Per Share--0.0000.000+100%0.000+33%0.000+54%0.000+169%
Enterprise Value--13312021.00034984773.250-62%94149959.000-86%151741238.800-91%180916241.629-93%
Eps---0.110-0.213+93%-0.099-10%-0.210+91%-0.124+13%
Ev To Ebitda Ratio---1.515-1.955+29%-4.887+223%-7.249+379%13.274-111%
Ev To Sales Ratio--3328.005993.167+235%infnan%infnan%infnan%
Free Cash Flow Per Share---0.068-0.078+14%-0.098+44%-0.090+33%-0.144+112%
Free Cash Flow To Equity Per Share---0.049-0.048-2%-0.017-65%0.002-2448%-0.091+87%
Gross Profit Margin--1.0001.046-4%1.020-2%1.013-1%1.008-1%
Intrinsic Value_10Y_max--0.264--------
Intrinsic Value_10Y_min---4.814--------
Intrinsic Value_1Y_max---0.336--------
Intrinsic Value_1Y_min---0.563--------
Intrinsic Value_3Y_max---0.733--------
Intrinsic Value_3Y_min---1.632--------
Intrinsic Value_5Y_max---0.798--------
Intrinsic Value_5Y_min---2.627--------
Market Cap9879510.590-53%15151021.00072751023.250-79%125910209.000-88%167471026.950-91%192862206.286-92%
Net Profit Margin---5759.000-1518.173-74%-117.892-98%-327.388-94%-187.130-97%
Operating Margin---2265.000-635.344-72%-111.824-95%-149.608-93%-85.541-96%
Operating Ratio--2698.000733.420+268%112.265+2303%169.347+1493%97.245+2674%
Pb Ratio5.808-53%8.907-10.066+213%32.175-72%22.644-61%36.601-76%
Pe Ratio-0.429+35%-0.658-2.553+288%-6.321+861%-7.083+977%-112.390+16988%
Price Per Share0.189-53%0.2901.393-79%2.410-88%3.206-91%3.679-92%
Price To Free Cash Flow Ratio-0.697+35%-1.068-5.230+389%-6.219+482%-9.242+765%-17.572+1545%
Price To Total Gains Ratio0.210-53%0.322-10.526+3372%-129.290+40294%804.803-100%624.543-100%
Quick Ratio--0.7370.545+35%0.847-13%2.005-63%1.477-50%
Return On Assets---1.093-1.198+10%-0.172-84%-0.549-50%-0.331-70%
Return On Equity---3.386-0.846-75%-1.556-54%-1.365-60%-0.844-75%
Total Gains Per Share--0.902-0.002+100%-0.047+105%-0.004+100%-0.003+100%
Usd Book Value--1701000.000-13907500.000+918%4260250.000-60%2978644.100-43%4070539.486-58%
Usd Book Value Change Per Share--0.901-0.003+100%-0.047+105%-0.004+100%-0.003+100%
Usd Book Value Per Share--0.033-0.266+918%0.082-60%0.057-43%0.073-55%
Usd Dividend Per Share--0.0000.000+100%0.000+33%0.000+54%0.000+169%
Usd Enterprise Value--13312021.00034984773.250-62%94149959.000-86%151741238.800-91%180916241.629-93%
Usd Eps---0.110-0.213+93%-0.099-10%-0.210+91%-0.124+13%
Usd Free Cash Flow---3545000.000-4051250.000+14%-5106750.000+44%-4699200.600+33%-38371371.771+982%
Usd Free Cash Flow Per Share---0.068-0.078+14%-0.098+44%-0.090+33%-0.144+112%
Usd Free Cash Flow To Equity Per Share---0.049-0.048-2%-0.017-65%0.002-2448%-0.091+87%
Usd Market Cap9879510.590-53%15151021.00072751023.250-79%125910209.000-88%167471026.950-91%192862206.286-92%
Usd Price Per Share0.189-53%0.2901.393-79%2.410-88%3.206-91%3.679-92%
Usd Profit---5759000.000-11134750.000+93%-5417000.000-6%-11226751.850+95%-6706801.057+16%
Usd Revenue--1000.000145500.000-99%17000.000-94%74329900.000-100%44827428.571-100%
Usd Total Gains Per Share--0.902-0.002+100%-0.047+105%-0.004+100%-0.003+100%
 EOD+2 -6MRQTTM+23 -17YOY+15 -245Y+17 -2210Y+18 -21

3.3 Fundamental Score

Let's check the fundamental score of Eterna Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-0.429
Price to Book Ratio (EOD)Between0-15.808
Net Profit Margin (MRQ)Greater than0-5,759.000
Operating Margin (MRQ)Greater than0-2,265.000
Quick Ratio (MRQ)Greater than10.737
Current Ratio (MRQ)Greater than10.801
Debt to Asset Ratio (MRQ)Less than10.677
Debt to Equity Ratio (MRQ)Less than12.098
Return on Equity (MRQ)Greater than0.15-3.386
Return on Assets (MRQ)Greater than0.05-1.093
Total1/10 (10.0%)

3.4 Technical Score

Let's check the technical score of Eterna Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.059
Ma 20Greater thanMa 500.237
Ma 50Greater thanMa 1000.295
Ma 100Greater thanMa 2000.377
OpenGreater thanClose0.176
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Eterna Therapeutics Inc

Ernexa Therapeutics Inc., a preclinical-stage company focused on using cutting-edge gene-editing tools to deliver highly innovative, effective, and safe off-the-shelf cell therapies for the treatment of advanced solid tumors. The company's lead product is ERNA-101, which is in preclinical stage for the treatment of ovarian cancer; and ERNA-102, that is in preclinical stage for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Fundamental data was last updated by Penke on 2025-04-04 19:02:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is unable to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Eterna Therapeutics Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Eterna Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -575,900.0%Β means thatΒ $-5,759.00 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Eterna Therapeutics Inc:

  • The MRQ is -575,900.0%. The company is making a huge loss. -2
  • The TTM is -151,817.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-575,900.0%TTM-151,817.3%-424,082.7%
TTM-151,817.3%YOY-11,789.2%-140,028.1%
TTM-151,817.3%5Y-32,738.8%-119,078.5%
5Y-32,738.8%10Y-18,713.0%-14,025.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-575,900.0%-109.6%-575,790.4%
TTM-151,817.3%-185.9%-151,631.4%
YOY-11,789.2%-206.2%-11,583.0%
5Y-32,738.8%-408.8%-32,330.0%
10Y-18,713.0%-522.9%-18,190.1%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Eterna Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Eterna Therapeutics Inc to theΒ Biotechnology industry mean.
  • -109.3% Return on Assets means thatΒ Eterna Therapeutics Inc generatedΒ $-1.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Eterna Therapeutics Inc:

  • The MRQ is -109.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -119.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-109.3%TTM-119.8%+10.5%
TTM-119.8%YOY-17.2%-102.7%
TTM-119.8%5Y-54.9%-65.0%
5Y-54.9%10Y-33.1%-21.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-109.3%-14.2%-95.1%
TTM-119.8%-14.6%-105.2%
YOY-17.2%-14.4%-2.8%
5Y-54.9%-15.5%-39.4%
10Y-33.1%-18.0%-15.1%
4.3.1.3. Return on Equity

Shows how efficient Eterna Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Eterna Therapeutics Inc to theΒ Biotechnology industry mean.
  • -338.6% Return on Equity means Eterna Therapeutics Inc generated $-3.39Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Eterna Therapeutics Inc:

  • The MRQ is -338.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -84.6%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-338.6%TTM-84.6%-253.9%
TTM-84.6%YOY-155.6%+71.0%
TTM-84.6%5Y-136.5%+51.8%
5Y-136.5%10Y-84.4%-52.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-338.6%-17.6%-321.0%
TTM-84.6%-18.2%-66.4%
YOY-155.6%-19.1%-136.5%
5Y-136.5%-24.3%-112.2%
10Y-84.4%-26.0%-58.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Eterna Therapeutics Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Eterna Therapeutics Inc is operatingΒ .

  • Measures how much profit Eterna Therapeutics Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Eterna Therapeutics Inc to theΒ Biotechnology industry mean.
  • An Operating Margin of -226,500.0%Β means the company generated $-2,265.00 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Eterna Therapeutics Inc:

  • The MRQ is -226,500.0%. The company is operating very inefficient. -2
  • The TTM is -63,534.4%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-226,500.0%TTM-63,534.4%-162,965.6%
TTM-63,534.4%YOY-11,182.4%-52,352.0%
TTM-63,534.4%5Y-14,960.8%-48,573.6%
5Y-14,960.8%10Y-8,554.1%-6,406.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-226,500.0%-223.7%-226,276.3%
TTM-63,534.4%-281.1%-63,253.3%
YOY-11,182.4%-226.6%-10,955.8%
5Y-14,960.8%-393.8%-14,567.0%
10Y-8,554.1%-503.6%-8,050.5%
4.3.2.2. Operating Ratio

Measures how efficient Eterna Therapeutics Inc is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 2,698.00 means that the operating costs are $2,698.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Eterna Therapeutics Inc:

  • The MRQ is 2,698.000. The company is inefficient in keeping operating costs low. -1
  • The TTM is 733.420. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2,698.000TTM733.420+1,964.580
TTM733.420YOY112.265+621.156
TTM733.4205Y169.347+564.073
5Y169.34710Y97.245+72.102
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2,698.0002.324+2,695.676
TTM733.4203.192+730.228
YOY112.2653.069+109.196
5Y169.3475.133+164.214
10Y97.2457.010+90.235
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Eterna Therapeutics Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Eterna Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 0.80Β means the company has $0.80 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Eterna Therapeutics Inc:

  • The MRQ is 0.801. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.611. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.801TTM0.611+0.190
TTM0.611YOY0.985-0.374
TTM0.6115Y2.201-1.590
5Y2.20110Y1.857+0.344
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8013.776-2.975
TTM0.6113.930-3.319
YOY0.9854.470-3.485
5Y2.2015.748-3.547
10Y1.8576.099-4.242
4.4.3.2. Quick Ratio

Measures if Eterna Therapeutics Inc is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Eterna Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Quick Ratio of 0.74Β means the company can pay off $0.74 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Eterna Therapeutics Inc:

  • The MRQ is 0.737. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.545. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.737TTM0.545+0.192
TTM0.545YOY0.847-0.301
TTM0.5455Y2.005-1.459
5Y2.00510Y1.477+0.528
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7373.102-2.365
TTM0.5453.367-2.822
YOY0.8474.358-3.511
5Y2.0055.731-3.726
10Y1.4776.427-4.950
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Eterna Therapeutics Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of Eterna Therapeutics IncΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Eterna Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.68Β means that Eterna Therapeutics Inc assets areΒ financed with 67.7% credit (debt) and the remaining percentage (100% - 67.7%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Eterna Therapeutics Inc:

  • The MRQ is 0.677. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 2.453. The company is unable to pay all its debts by selling its assets. -2
Trends
Current periodCompared to+/- 
MRQ0.677TTM2.453-1.776
TTM2.453YOY0.829+1.624
TTM2.4535Y1.079+1.374
5Y1.07910Y0.903+0.175
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6770.340+0.337
TTM2.4530.340+2.113
YOY0.8290.318+0.511
5Y1.0790.364+0.715
10Y0.9030.393+0.510
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Eterna Therapeutics Inc is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Eterna Therapeutics Inc to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 209.8% means that company has $2.10 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Eterna Therapeutics Inc:

  • The MRQ is 2.098. The company is just not able to pay all its debts with equity.
  • The TTM is 0.524. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ2.098TTM0.524+1.573
TTM0.524YOY11.716-11.191
TTM0.5245Y4.014-3.489
5Y4.01410Y3.369+0.645
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0980.399+1.699
TTM0.5240.407+0.117
YOY11.7160.389+11.327
5Y4.0140.428+3.586
10Y3.3690.460+2.909
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Eterna Therapeutics Inc generates.

  • Above 15 is considered overpriced butΒ always compareΒ Eterna Therapeutics Inc to theΒ Biotechnology industry mean.
  • A PE ratio of -0.66 means the investor is paying $-0.66Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Eterna Therapeutics Inc:

  • The EOD is -0.429. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.658. Based on the earnings, the company is expensive. -2
  • The TTM is -2.553. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.429MRQ-0.658+0.229
MRQ-0.658TTM-2.553+1.895
TTM-2.553YOY-6.321+3.768
TTM-2.5535Y-7.083+4.530
5Y-7.08310Y-112.390+105.307
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.429-1.736+1.307
MRQ-0.658-2.674+2.016
TTM-2.553-3.229+0.676
YOY-6.321-3.337-2.984
5Y-7.083-6.386-0.697
10Y-112.390-7.280-105.110
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Eterna Therapeutics Inc:

  • The EOD is -0.697. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -1.068. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.230. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-0.697MRQ-1.068+0.372
MRQ-1.068TTM-5.230+4.162
TTM-5.230YOY-6.219+0.989
TTM-5.2305Y-9.242+4.012
5Y-9.24210Y-17.572+8.330
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-0.697-2.257+1.560
MRQ-1.068-3.660+2.592
TTM-5.230-4.254-0.976
YOY-6.219-4.479-1.740
5Y-9.242-8.682-0.560
10Y-17.572-9.845-7.727
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Eterna Therapeutics Inc is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 8.91 means the investor is paying $8.91Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Eterna Therapeutics Inc:

  • The EOD is 5.808. Based on the equity, the company is overpriced. -1
  • The MRQ is 8.907. Based on the equity, the company is overpriced. -1
  • The TTM is -10.066. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.808MRQ8.907-3.099
MRQ8.907TTM-10.066+18.973
TTM-10.066YOY32.175-42.241
TTM-10.0665Y22.644-32.710
5Y22.64410Y36.601-13.957
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.8081.641+4.167
MRQ8.9072.266+6.641
TTM-10.0662.443-12.509
YOY32.1752.468+29.707
5Y22.6443.790+18.854
10Y36.6014.287+32.314
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Eterna Therapeutics Inc.

4.8.1. Institutions holding Eterna Therapeutics Inc

Institutions are holding 1.903% of the shares of Eterna Therapeutics Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31CI Private Wealth LLC0.51150.000126286200
2024-12-31Geode Capital Management, LLC0.500702573102368751159.1632
2024-12-31Cypress Point Wealth Management, LLC0.18370.00869437500
2024-12-31XTX Topco Ltd0.11310.001458102581020
2024-12-31Sippican Capital Adivsors0.09730.010750000-18504-27.0116
2024-12-31Naviter Wealth, LLC0.0920.001747271-31525-40.0084
2024-12-31Millennium Management LLC0.0877045046450460
2024-12-31Susquehanna International Group, LLP0.0607031167311670
2024-12-31TWO SIGMA SECURITIES, LLC0.05790.001229736-3124-9.507
2024-12-31Vanguard Group Inc0.050802609900
2024-12-31Cubist Systematic Strategies, LLC0.0416021365213650
2024-12-31UBS Group AG0.0328016857-66763-79.8409
2024-12-31BlackRock Inc0.02901491900
2024-12-31Streettalk Advisors LLC0.02880.00021479800
2024-12-31Goldman Sachs Group Inc0.0249012813128130
2024-12-31one8zero8, LLC0.02120.000710873108730
2024-12-31Bank of America Corp0.00060295172139.8374
2024-12-31A. Montag & Associates Inc0.0004021200
2024-12-31BNP Paribas Arbitrage, SA0.000301401400
2024-12-31JPMorgan Chase & Co0.000105931110.7143
Total 1.93510.0246994299+296668+29.8%

4.9.2. Funds holding Eterna Therapeutics Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2025-01-31Fidelity Extended Market Index0.41040.0002210896-3204-1.4965
2025-01-31Spartan Extended Market Index Pool E0.07890.00024055232048.5788
2025-02-28Vanguard Institutional Extnd Mkt Idx Tr0.050802609900
2025-02-28Vanguard Total Stock Mkt Idx Inv0.023501209100
2025-01-31Fidelity Series Total Market Index0.00610312900
2024-12-31Extended Equity Market Fund K0.004402252-31-1.3579
2025-01-31Fidelity Total Market Index0.0040204700
2024-12-31NT Ext Equity Mkt Idx Fd - NL0.00230115900
2024-12-31NT Ext Equity Mkt Idx Fd - L0.00220111300
2024-12-31Northern Trust Extended Eq Market Idx0.00220111300
2024-12-31NT Ext Equity Mkt Idx Fd - DC - NL - T20.00180919-15-1.606
2025-02-28State St US Extended Mkt Indx NL Cl C0.0015076600
2025-01-31Spartan Total Market Index Pool E0.0013064300
2024-06-30SSgA U.S. Total Market Index Strategy0.000603149342.0814
2024-12-31Extended Equity Market Fund M0.0006029231.0381
2024-12-31BNYM Mellon SL Market Completion UC10.0005028251.8051
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T30.000502652650
2024-12-31NT Ext Eq Mkt Indx Fd DC Lend T40.000502652650
2024-09-30NT Ext Eq Mkt Indx Fd DC Lending Tier 50.0003017200
2024-12-31Northern Trust Wilshire 50000.0003016600
Total 0.59270.0004304535+585+0.2%

5.3. Insider Transactions

Insiders are holding 74.942% of the shares of Eterna Therapeutics Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-12-02John D HalpernBUY3359203.28
2022-12-02Nicholas Jason SingerBUY2832863.28
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-12-312024-03-312024-06-302024-09-302024-12-31
Net Debt  34,2688,06942,3374,28246,619-17,33529,284-30,329-1,045



5.2. Latest Balance Sheet

Balance Sheet of 2024-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets5,269
Total Liabilities3,568
Total Stockholder Equity1,701
 As reported
Total Liabilities 3,568
Total Stockholder Equity+ 1,701
Total Assets = 5,269

Assets

Total Assets5,269
Total Current Assets2,352
Long-term Assets2,917
Total Current Assets
Cash And Cash Equivalents 1,729
Net Receivables 437
Other Current Assets 186
Total Current Assets  (as reported)2,352
Total Current Assets  (calculated)2,352
+/-0
Long-term Assets
Property Plant Equipment 755
Goodwill 2,044
Long-term Assets Other 118
Long-term Assets  (as reported)2,917
Long-term Assets  (calculated)2,917
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,938
Long-term Liabilities630
Total Stockholder Equity1,701
Total Current Liabilities
Short-term Debt 207
Accounts payable 1,721
Other Current Liabilities 1,007
Total Current Liabilities  (as reported)2,938
Total Current Liabilities  (calculated)2,935
+/- 3
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt477
Long-term Liabilities Other 152
Long-term Liabilities  (as reported)630
Long-term Liabilities  (calculated)629
+/- 1
Total Stockholder Equity
Common Stock257
Retained Earnings -231,536
Other Stockholders Equity 232,979
Total Stockholder Equity (as reported)1,701
Total Stockholder Equity (calculated)1,700
+/- 1
Other
Capital Stock258
Cash and Short Term Investments 1,729
Common Stock Shares Outstanding 13,647
Liabilities and Stockholders Equity 5,269
Net Debt -1,045
Net Invested Capital 1,700
Net Working Capital -586
Property Plant and Equipment Gross 927
Short Long Term Debt Total 684



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-30
> Total Assets 
29,138
29,143
26,525
25,537
24,331
23,318
20,860
17,502
15,794
14,468
11,662
11,658
14,715
14,159
14,297
13,901
13,145
13,503
13,125
13,554
12,874
12,197
11,647
13,110
12,271
12,626
12,656
11,832
11,377
11,649
15,457
15,520
22,576
22,565
22,268
20,158
17,239
17,282
16,408
16,316
14,956
14,398
16,695
17,534
18,532
17,563
16,570
15,701
16,356
15,544
14,864
16,475
15,639
14,919
14,125
11,014
6,790
5,054
12,906
20,698
64,710
39,394
32,429
32,429
32,429
20,926
22,279
15,108
46,954
52,248
49,132
49,657
46,486
7,718
5,269
5,2697,71846,48649,65749,13252,24846,95415,10822,27920,92632,42932,42932,42939,39464,71020,69812,9065,0546,79011,01414,12514,91915,63916,47514,86415,54416,35615,70116,57017,56318,53217,53416,69514,39814,95616,31616,40817,28217,23920,15822,26822,56522,57615,52015,45711,64911,37711,83212,65612,62612,27113,11011,64712,19712,87413,55413,12513,50313,14513,90114,29714,15914,71511,65811,66214,46815,79417,50220,86023,31824,33125,53726,52529,14329,138
   > Total Current Assets 
13,344
14,084
16,058
16,095
15,381
15,086
12,903
9,813
8,368
6,834
4,667
4,696
5,559
5,222
5,138
4,789
4,626
5,217
5,227
5,514
4,140
3,484
2,798
4,442
3,754
4,323
4,229
3,811
3,586
3,893
7,918
7,811
15,455
15,331
14,872
12,648
9,738
9,669
9,110
9,135
8,224
7,761
10,662
11,635
12,223
10,745
9,638
8,728
9,213
8,529
6,785
6,208
5,713
5,547
6,070
4,265
4,089
2,793
1,732
8,714
51,941
25,758
18,766
18,766
18,766
15,852
13,681
6,515
3,891
7,031
9,599
6,164
3,583
4,730
2,352
2,3524,7303,5836,1649,5997,0313,8916,51513,68115,85218,76618,76618,76625,75851,9418,7141,7322,7934,0894,2656,0705,5475,7136,2086,7858,5299,2138,7289,63810,74512,22311,63510,6627,7618,2249,1359,1109,6699,73812,64814,87215,33115,4557,8117,9183,8933,5863,8114,2294,3233,7544,4422,7983,4844,1405,5145,2275,2174,6264,7895,1385,2225,5594,6964,6676,8348,3689,81312,90315,08615,38116,09516,05814,08413,344
       Cash And Cash Equivalents 
6,746
7,997
0
11,052
11,395
10,771
10,273
7,854
6,616
5,257
3,362
3,311
3,845
3,217
3,637
3,105
3,268
3,855
3,906
4,033
3,085
2,462
1,374
3,143
2,549
2,405
2,721
2,324
1,973
2,168
5,455
4,761
11,164
9,840
7,185
7,163
5,391
4,678
3,223
3,549
3,571
3,016
5,686
6,113
6,834
4,464
3,378
2,635
3,785
3,078
2,536
2,666
2,727
2,533
3,209
2,221
2,234
1,710
1,630
8,410
50,165
24,382
16,985
16,985
16,985
13,254
11,446
5,397
1,837
4,551
7,575
5,116
2,586
4,264
1,729
1,7294,2642,5865,1167,5754,5511,8375,39711,44613,25416,98516,98516,98524,38250,1658,4101,6301,7102,2342,2213,2092,5332,7272,6662,5363,0783,7852,6353,3784,4646,8346,1135,6863,0163,5713,5493,2234,6785,3917,1637,1859,84011,1644,7615,4552,1681,9732,3242,7212,4052,5493,1431,3742,4623,0854,0333,9063,8553,2683,1053,6373,2173,8453,3113,3625,2576,6167,85410,27310,77111,39511,05207,9976,746
       Net Receivables 
3,279
2,833
0
1,099
924
1,309
1,354
1,100
1,051
862
636
614
774
1,106
606
1,003
547
451
549
499
475
516
750
662
640
1,086
610
573
478
533
641
1,115
884
840
2,190
645
546
575
919
769
641
898
928
1,765
761
627
714
1,033
787
1,279
1,143
848
732
777
1,195
383
186
132
116
53
23
23
684
684
684
926
951
647
984
1,776
425
351
228
187
437
4371872283514251,7769846479519266846846842323531161321863831,1957777328481,1431,2797871,0337146277611,7659288986417699195755466452,1908408841,1156415334785736101,0866406627505164754995494515471,0036061,1067746146368621,0511,1001,3541,3099241,09902,8333,279
       Inventory 
336
376
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-116
0
0
0
0
0
0
0
-951
0
0
0
0
0
0
0
0
00000000-9510000000-11600000000000000000000000000000000000000000000000000000000376336
       Other Current Assets 
2,983
2,878
16,058
3,944
3,062
3,006
1,276
859
701
715
669
771
940
899
895
681
811
911
772
982
580
506
674
637
565
832
898
914
1,135
1,192
1,822
1,935
3,407
4,651
5,497
4,840
3,801
4,416
4,968
4,817
4,012
3,847
4,048
3,757
4,628
5,654
5,546
5,060
4,641
4,172
3,106
2,694
2,254
2,237
1,666
1,661
1,669
951
102
250
1,753
1,353
1,097
1,097
1,097
1,672
2,235
471
1,070
704
1,599
697
769
279
186
1862797696971,5997041,0704712,2351,6721,0971,0971,0971,3531,7532501029511,6691,6611,6662,2372,2542,6943,1064,1724,6415,0605,5465,6544,6283,7574,0483,8474,0124,8174,9684,4163,8014,8405,4974,6513,4071,9351,8221,1921,1359148988325656376745065809827729118116818958999407716697157018591,2763,0063,0623,94416,0582,8782,983
   > Long-term Assets 
15,794
15,059
10,467
9,442
8,950
8,232
7,957
7,689
7,426
7,634
6,995
6,962
9,156
8,937
9,159
9,112
8,519
8,286
7,898
8,040
8,734
8,713
8,849
8,668
8,517
8,303
8,427
8,021
7,791
7,756
7,539
7,709
7,121
7,234
7,396
7,510
7,501
7,613
7,298
7,181
6,732
6,637
6,033
5,899
6,309
6,818
6,932
6,973
7,143
7,015
8,079
10,267
9,926
9,372
8,055
6,749
2,701
2,261
11,174
11,984
12,768
13,636
13,662
13,662
13,663
5,074
8,598
8,593
43,063
45,217
39,533
43,493
42,903
2,988
2,917
2,9172,98842,90343,49339,53345,21743,0638,5938,5985,07413,66313,66213,66213,63612,76811,98411,1742,2612,7016,7498,0559,3729,92610,2678,0797,0157,1436,9736,9326,8186,3095,8996,0336,6376,7327,1817,2987,6137,5017,5107,3967,2347,1217,7097,5397,7567,7918,0218,4278,3038,5178,6688,8498,7138,7348,0407,8988,2868,5199,1129,1598,9379,1566,9626,9957,6347,4267,6897,9578,2328,9509,44210,46715,05915,794
       Property Plant Equipment 
7,436
6,952
0
5,123
4,929
4,675
4,101
4,113
3,701
3,659
3,428
3,375
3,496
3,748
3,809
4,216
3,901
3,845
3,638
3,622
4,319
4,250
4,255
4,212
4,219
3,915
3,783
3,534
3,305
3,227
3,237
3,423
3,423
3,334
3,400
3,571
3,710
4,032
3,915
3,799
3,511
3,467
3,101
2,910
3,159
3,485
3,678
3,753
3,922
3,645
4,667
6,583
6,090
5,541
4,923
4,491
972
694
2,687
2,592
3,350
3,213
3,236
3,236
3,237
2,143
1,266
1,204
35,550
35,033
33,274
37,234
36,644
824
755
75582436,64437,23433,27435,03335,5501,2041,2662,1433,2373,2363,2363,2133,3502,5922,6876949724,4914,9235,5416,0906,5834,6673,6453,9223,7533,6783,4853,1592,9103,1013,4673,5113,7993,9154,0323,7103,5713,4003,3343,4233,4233,2373,2273,3053,5343,7833,9154,2194,2124,2554,2504,3193,6223,6383,8453,9014,2163,8093,7483,4963,3753,4283,6593,7014,1134,1014,6754,9295,12306,9527,436
       Goodwill 
3,658
3,658
0
974
974
1,271
1,285
1,233
1,248
1,215
1,032
1,009
1,091
1,161
1,202
1,237
1,203
1,225
1,261
1,296
1,291
1,221
1,236
1,264
1,230
1,281
1,265
1,238
1,197
1,222
1,179
1,139
1,181
1,130
1,084
997
1,020
940
909
972
973
959
937
946
968
1,012
1,004
978
955
976
667
681
695
687
696
0
0
0
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,044
2,0442,0442,0442,0442,0442,0442,0442,0442,0442,0442,0442,0442,0442,0442,0442,0442,0440006966876956816679769559781,0041,0129689469379599739729099401,0209971,0841,1301,1811,1391,1791,2221,1971,2381,2651,2811,2301,2641,2361,2211,2911,2961,2611,2251,2031,2371,2021,1611,0911,0091,0321,2151,2481,2331,2851,27197497403,6583,658
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,000
1,000
385
89
68
59
8
0
0
0
0
0
0
0
000000085968893851,0001,0000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
2,570
2,383
0
1,441
1,327
386
318
284
263
234
185
171
1,927
1,601
1,585
1,325
1,221
1,123
1,025
928
827
720
845
753
658
567
579
468
363
259
160
95
48
154
129
117
104
92
79
67
54
42
29
17
4
0
0
0
0
0
0
0
0
0
0
0
0
0
5,990
6,860
6,860
6,860
6,860
6,860
6,860
0
0
0
0
0
0
0
0
0
0
00000000006,8606,8606,8606,8606,8606,8605,990000000000000041729425467799210411712915448951602593634685795676587538457208279281,0251,1231,2211,3251,5851,6011,9271711852342632843183861,3271,44102,3832,570
       Long-term Assets Other 
2,130
2,066
10,467
1,904
1,720
1,900
2,253
2,059
2,214
2,526
2,350
2,407
2,642
2,427
2,563
2,334
2,194
2,093
1,974
2,194
2,297
2,522
2,513
2,439
2,410
2,540
2,800
2,781
2,926
3,048
2,963
3,052
2,469
2,616
2,783
2,825
2,667
2,549
2,395
2,343
2,194
2,169
1,966
2,026
2,178
2,321
2,250
2,242
2,266
2,394
2,745
3,003
3,141
3,144
2,436
2,258
1,729
1,567
453
489
515
519
522
522
522
819
5,229
5,337
5,469
8,140
120
120
120
120
118
1181201201201208,1405,4695,3375,2298195225225225195154894531,5671,7292,2582,4363,1443,1413,0032,7452,3942,2662,2422,2502,3212,1782,0261,9662,1692,1942,3432,3952,5492,6672,8252,7832,6162,4693,0522,9633,0482,9262,7812,8002,5402,4102,4392,5132,5222,2972,1941,9742,0932,1942,3342,5632,4272,6422,4072,3502,5262,2142,0592,2531,9001,7201,90410,4672,0662,130
> Total Liabilities 
8,467
8,017
7,995
7,622
5,816
5,815
5,292
4,878
5,379
5,116
3,916
4,228
4,860
4,787
4,879
4,724
4,353
4,499
3,664
4,518
4,753
4,922
5,297
5,372
5,161
5,356
4,762
4,327
4,011
4,407
6,255
6,981
8,860
9,956
11,344
11,549
11,094
12,502
12,560
13,283
12,672
12,604
12,627
11,706
12,498
11,505
11,034
10,505
9,820
8,648
7,947
9,784
8,972
8,574
9,034
7,165
4,859
4,559
5,247
25,119
29,527
26,354
25,927
25,927
25,927
12,113
10,172
7,728
43,088
48,686
46,899
53,069
55,012
53,111
3,568
3,56853,11155,01253,06946,89948,68643,0887,72810,17212,11325,92725,92725,92726,35429,52725,1195,2474,5594,8597,1659,0348,5748,9729,7847,9478,6489,82010,50511,03411,50512,49811,70612,62712,60412,67213,28312,56012,50211,09411,54911,3449,9568,8606,9816,2554,4074,0114,3274,7625,3565,1615,3725,2974,9224,7534,5183,6644,4994,3534,7244,8794,7874,8604,2283,9165,1165,3794,8785,2925,8155,8167,6227,9958,0178,467
   > Total Current Liabilities 
8,010
7,664
7,729
7,432
5,646
5,664
5,205
4,789
5,289
5,034
3,793
3,808
4,043
4,050
4,257
4,165
3,955
4,140
3,336
4,235
3,920
3,844
3,868
3,937
3,655
3,870
3,388
3,002
2,642
2,905
3,608
4,555
5,374
6,083
7,093
7,667
4,842
5,707
5,122
6,843
6,582
6,560
6,643
10,522
11,646
10,937
10,747
7,339
7,137
5,542
4,024
4,057
3,574
3,532
6,095
4,352
3,195
2,930
3,125
3,902
7,684
4,561
3,677
3,677
3,677
7,467
7,654
5,406
7,165
9,626
6,573
7,768
9,600
9,952
2,938
2,9389,9529,6007,7686,5739,6267,1655,4067,6547,4673,6773,6773,6774,5617,6843,9023,1252,9303,1954,3526,0953,5323,5744,0574,0245,5427,1377,33910,74710,93711,64610,5226,6436,5606,5826,8435,1225,7074,8427,6677,0936,0835,3744,5553,6082,9052,6423,0023,3883,8703,6553,9373,8683,8443,9204,2353,3364,1403,9554,1654,2574,0504,0433,8083,7935,0345,2894,7895,2055,6645,6467,4327,7297,6648,010
       Short-term Debt 
439
412
0
251
144
15
7
999
1,071
1,122
8
676
770
772
300
435
440
407
376
322
291
303
286
265
215
160
100
57
34
25
656
728
1,481
1,846
2,204
2,093
600
955
1,150
3,123
3,089
3,053
3,143
7,461
5,352
5,318
5,235
2,119
2,377
1,260
1,045
1,276
1,471
1,434
2,760
2,396
1,672
1,752
799
930
1,104
818
426
426
426
439
2,045
1,918
1,923
2,792
4,432
5,748
8,532
201
207
2072018,5325,7484,4322,7921,9231,9182,0454394264264268181,1049307991,7521,6722,3962,7601,4341,4711,2761,0451,2602,3772,1195,2355,3185,3527,4613,1433,0533,0893,1231,1509556002,0932,2041,8461,48172865625345710016021526528630329132237640744043530077277067681,1221,0719997151442510412439
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
410
0
0
0
0
1,750
1,750
1,750
1,643
0
0
0
776
0
07760001,6431,7501,7501,75000004100000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
858
839
0
1,039
337
610
831
1,054
601
739
219
482
722
347
422
865
928
911
423
792
758
752
528
727
670
645
549
152
145
141
553
795
797
572
617
577
465
396
211
171
379
430
247
513
1,022
579
390
521
427
341
271
480
283
335
835
787
397
275
1,275
1,812
3,679
996
1,755
1,755
1,755
1,150
1,620
1,461
2,675
1,464
1,067
2,063
2,193
2,193
1,721
1,7212,1932,1932,0631,0671,4642,6751,4611,6201,1501,7551,7551,7559963,6791,8121,2752753977878353352834802713414275213905791,0225132474303791712113964655776175727977955531411451525496456707275287527587924239119288654223477224822197396011,0548316103371,0390839858
       Other Current Liabilities 
4,420
4,096
7,729
4,938
4,068
3,734
3,395
1,939
2,820
2,363
2,909
1,975
1,920
2,359
3,012
2,490
2,158
2,142
2,017
2,524
2,304
2,252
2,591
2,446
2,206
2,454
1,820
2,251
1,917
2,224
1,806
1,973
1,722
2,044
2,436
2,677
1,970
2,373
2,547
2,274
1,761
1,698
2,194
1,511
1,436
1,326
1,558
1,298
1,484
1,454
1,337
1,107
1,302
1,020
2,040
786
749
783
1,051
1,160
985
618
1,496
1,496
1,496
5,878
3,989
1,777
2,317
3,555
882
-238
-1,321
7,540
1,007
1,0077,540-1,321-2388823,5552,3171,7773,9895,8781,4961,4961,4966189851,1601,0517837497862,0401,0201,3021,1071,3371,4541,4841,2981,5581,3261,4361,5112,1941,6981,7612,2742,5472,3731,9702,6772,4362,0441,7221,9731,8062,2241,9172,2511,8202,4542,2062,4462,5912,2522,3042,5242,0172,1422,1582,4903,0122,3591,9201,9752,9092,3632,8201,9393,3953,7344,0684,9387,7294,0964,420
   > Long-term Liabilities 
457
353
266
190
170
151
87
89
90
82
123
420
817
737
622
559
398
359
328
283
833
1,078
1,429
1,435
1,506
1,486
1,374
1,325
1,369
1,502
2,647
2,426
3,486
3,873
4,251
3,882
6,252
6,795
7,438
6,440
6,090
6,044
5,984
1,184
852
568
287
3,166
2,683
3,106
3,923
5,727
5,398
5,042
3,322
2,813
1,664
1,629
2,122
21,217
21,842
21,794
22,250
22,250
22,250
4,646
2,517
2,322
35,923
39,060
40,326
45,301
45,412
43,159
630
63043,15945,41245,30140,32639,06035,9232,3222,5174,64622,25022,25022,25021,79421,84221,2172,1221,6291,6642,8133,3225,0425,3985,7273,9233,1062,6833,1662875688521,1845,9846,0446,0906,4407,4386,7956,2523,8824,2513,8733,4862,4262,6471,5021,3691,3251,3741,4861,5061,4351,4291,07883328332835939855962273781742012382908987151170190266353457
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,383
48
13,363
2,572
2,323
1,631
0
960
0
0
0
0
0
0
00000096001,6312,3232,57213,3634819,3830000000000000000000000000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,860
5,990
5,990
0
0
0
0
0
0
0
0
0
0
0
000000000005,9905,9906,8600000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
20,671
21,126
18,530
17,915
18,515
17,503
15,568
12,624
10,415
9,352
7,746
7,430
9,855
9,372
9,418
9,177
8,792
9,004
9,461
9,036
8,121
7,275
6,350
7,738
7,110
7,270
7,894
7,505
7,366
7,242
9,202
8,539
13,716
12,609
10,924
8,609
6,145
4,780
3,848
3,033
2,284
1,794
4,068
5,828
6,034
6,058
5,536
5,196
6,536
6,896
6,917
6,691
6,667
6,345
5,091
3,849
1,931
495
7,659
-4,421
35,183
13,040
6,502
6,502
6,502
8,813
12,107
7,380
3,866
3,562
2,233
-3,412
-8,526
-45,393
1,701
1,701-45,393-8,526-3,4122,2333,5623,8667,38012,1078,8136,5026,5026,50213,04035,183-4,4217,6594951,9313,8495,0916,3456,6676,6916,9176,8966,5365,1965,5366,0586,0345,8284,0681,7942,2843,0333,8484,7806,1458,60910,92412,60913,7168,5399,2027,2427,3667,5057,8947,2707,1107,7386,3507,2758,1219,0369,4619,0048,7929,1779,4189,3729,8557,4307,7469,35210,41512,62415,56817,50318,51517,91518,53021,12620,671
   Common Stock
270
271
0
273
277
277
277
277
277
277
277
277
300
300
0
303
0
303
304
304
304
304
305
355
355
355
355
357
358
359
393
394
458
461
462
462
462
462
462
462
9
9
11
12
13
13
13
13
14
14
14
14
14
14
14
15
15
15
25,800
208
224
260
260
260
260
15
26
26
27
27
27
27
27
27
257
25727272727272726261526026026026022420825,8001515151414141414141413131313121199462462462462462462461458394393359358357355355355355305304304304304303030303003002772772772772772772772772730271270
   Retained Earnings -231,536-225,769-199,165-193,628-186,981-180,820-175,229-170,713-165,297-160,799-159,703-159,703-159,703-151,232-65,176-55,083-18,141-136,187-134,706-132,675-131,457-130,156-129,805-129,707-129,394-129,438-129,660-129,528-129,119-128,472-128,288-128,116-128,026-127,559-126,986-126,128-125,087-124,089-122,741-120,108-117,845-116,119-114,804-113,448-112,799-112,440-112,206-112,099-111,730-112,351-112,405-111,764-110,719-109,672-108,835-107,843-107,284-107,598-107,722-107,257-106,868-106,664-105,896-105,606-105,351-104,646-103,789-101,444-98,870-96,667-94,882-94,3280-90,623-90,568
   Accumulated Other Comprehensive Income 
134
231
0
154
574
1,641
1,662
1,170
1,211
976
8
-92
267
505
699
731
707
738
782
811
797
699
0
767
713
795
0
727
662
701
0
568
636
553
0
326
368
228
0
285
287
262
0
238
279
359
0
297
254
293
0
233
265
247
0
164
240
241
0
0
0
0
0
0
0
0
0
0
-1
-1
-27
-1
-1
0
0
00-1-1-27-1-10000000000241240164024726523302932542970359279238026228728502283683260553636568070166272707957137670699797811782738707731699505267-9289761,2111,1701,6621,6415741540231134
   Capital Surplus 000000000000000000000000000000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
110,834
111,246
18,530
111,815
112,545
112,251
112,498
112,620
112,715
112,744
112,811
112,850
115,183
115,230
115,587
115,399
115,807
115,560
115,658
115,763
115,854
115,943
116,764
118,379
118,446
118,470
119,269
118,519
118,551
118,621
121,608
121,024
127,425
127,713
128,307
127,928
128,055
128,178
128,473
128,413
128,973
129,081
132,083
133,693
134,029
134,157
134,642
134,413
135,927
136,026
136,297
136,150
136,192
136,239
136,534
136,344
136,381
136,425
0
50,453
100,135
164,011
165,944
165,944
165,944
169,596
177,376
178,066
179,068
184,355
189,186
190,189
190,612
180,348
232,979
232,979180,348190,612190,189189,186184,355179,068178,066177,376169,596165,944165,944165,944164,011100,13550,4530136,425136,381136,344136,534136,239136,192136,150136,297136,026135,927134,413134,642134,157134,029133,693132,083129,081128,973128,413128,473128,178128,055127,928128,307127,713127,425121,024121,608118,621118,551118,519119,269118,470118,446118,379116,764115,943115,854115,763115,658115,560115,807115,399115,587115,230115,183112,850112,811112,744112,715112,620112,498112,251112,545111,81518,530111,246110,834



5.4. Balance Sheets

Currency in USD. All numbers in thousands.




5.5. Cash Flows

Currency in USD. All numbers in thousands.




5.6. Income Statements

Currency in USD. All numbers in thousands.


5.7. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue582
Cost of Revenue-96
Gross Profit486486
 
Operating Income (+$)
Gross Profit486
Operating Expense-16,160
Operating Income-15,674-15,674
 
Operating Expense (+$)
Research Development4,604
Selling General Administrative13,132
Selling And Marketing Expenses0
Operating Expense16,16017,736
 
Net Interest Income (+$)
Interest Income249
Interest Expense-6,752
Other Finance Cost-0
Net Interest Income-6,503
 
Pretax Income (+$)
Operating Income-15,674
Net Interest Income-6,503
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-44,50913,161
EBIT - interestExpense = -44,509
-44,509
-37,787
Interest Expense6,752
Earnings Before Interest and Taxes (EBIT)-37,757-37,757
Earnings Before Interest and Taxes (EBITDA)-36,119
 
After tax Income (+$)
Income Before Tax-44,509
Tax Provision-30
Net Income From Continuing Ops-44,539-44,539
Net Income-44,539
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses16,256
Total Other Income/Expenses Net-28,8356,503
 

Technical Analysis of Eterna Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Eterna Therapeutics Inc. The general trend of Eterna Therapeutics Inc is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Eterna Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Eterna Therapeutics Inc Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Eterna Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.22 < 0.25 < 0.25.

The bearish price targets are: .

Know someone who trades $ERNA? Share this with them.πŸ‘‡

Eterna Therapeutics Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Eterna Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Eterna Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Eterna Therapeutics Inc. The current macd is -0.03232036.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Eterna Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Eterna Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Eterna Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Eterna Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartEterna Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Eterna Therapeutics Inc. The current adx is 24.84.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Eterna Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Eterna Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Eterna Therapeutics Inc. The current sar is 0.23298659.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Eterna Therapeutics Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Eterna Therapeutics Inc. The current rsi is 33.06. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Eterna Therapeutics Inc Daily Relative Strength Index (RSI) ChartEterna Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Eterna Therapeutics Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Eterna Therapeutics Inc price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Eterna Therapeutics Inc Daily Stochastic Oscillator ChartEterna Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Eterna Therapeutics Inc. The current cci is -123.60828686.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Eterna Therapeutics Inc Daily Commodity Channel Index (CCI) ChartEterna Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Eterna Therapeutics Inc. The current cmo is -37.12934191.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Eterna Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartEterna Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Eterna Therapeutics Inc. The current willr is -70.24729521.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Eterna Therapeutics Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Eterna Therapeutics Inc Daily Williams %R ChartEterna Therapeutics Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Eterna Therapeutics Inc.

Eterna Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Eterna Therapeutics Inc. The current atr is 0.03246833.

Eterna Therapeutics Inc Daily Average True Range (ATR) ChartEterna Therapeutics Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Eterna Therapeutics Inc. The current obv is 536,785,574.

Eterna Therapeutics Inc Daily On-Balance Volume (OBV) ChartEterna Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Eterna Therapeutics Inc. The current mfi is 13.75.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
Eterna Therapeutics Inc Daily Money Flow Index (MFI) ChartEterna Therapeutics Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Eterna Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-11MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-14SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-09STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-23STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-24MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-12-26SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-27STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-12-30RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-01-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-01-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-01-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-01-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-01-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-10STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-13MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-14MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-19CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-20CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-03STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-10DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-12MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-03-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-03-28ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-31STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-01MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-04-02RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2025-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-04-04RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Eterna Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Eterna Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5033.059
Ma 20Greater thanMa 500.237
Ma 50Greater thanMa 1000.295
Ma 100Greater thanMa 2000.377
OpenGreater thanClose0.176
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Eterna Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Eterna Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Eterna Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Eterna Therapeutics Inc

I send you an email if I find something interesting about Eterna Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Eterna Therapeutics Inc.

Receive notifications about Eterna Therapeutics Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.